Daniel Torres-Moreno
Overview
Explore the profile of Daniel Torres-Moreno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kinoshita H, Martinez-Ordonez A, Cid-Diaz T, Han Q, Duran A, Muta Y, et al.
Dev Cell
. 2024 May;
59(15):1972-1987.e8.
PMID: 38815584
The early mechanisms of spontaneous tumor initiation that precede malignancy are largely unknown. We show that reduced aPKC levels correlate with stem cell loss and the induction of revival and...
2.
Muta Y, Linares J, Martinez-Ordonez A, Duran A, Cid-Diaz T, Kinoshita H, et al.
Nat Commun
. 2023 Dec;
14(1):8075.
PMID: 38092754
The metabolic and signaling pathways regulating aggressive mesenchymal colorectal cancer (CRC) initiation and progression through the serrated route are largely unknown. Although relatively well characterized as BRAF mutant cancers, their...
3.
Santaclara V, Torres-Moreno D, Bernal-Manas C, Isaac M, Ortiz-Reina S, Conesa-Zamora P
Hum Immunol
. 2021 Jun;
82(9):621-624.
PMID: 34127318
Squamous intraepithelial lesions (SIL) and cervical cancer are primary due to suboptimal immune response against human papillomavirus (HPV). The FASL/FAS system is a trigger of extrinsic pathway apoptosis. The distribution...
4.
Garcia-Solano J, Turpin-Sevilla M, Garcia-Garcia F, Carbonell-Munoz R, Torres-Moreno D, Conesa A, et al.
Histopathology
. 2019 Apr;
75(4):496-507.
PMID: 31025430
Aims: To discern the differences in expression profiling of two histological subtypes of colorectal carcinoma (CRC) arising from the serrated route (serrated adenocarcinoma (SAC) and CRC showing histological and molecular...
5.
Garcia-Solano J, Turpin M, Torres-Moreno D, Huertas-Lopez F, Tuomisto A, Makinen M, et al.
Clin Epigenetics
. 2018 Nov;
10(1):141.
PMID: 30413173
Background: Altered methylation patterns are driving forces in colorectal carcinogenesis. The serrated adenocarcinoma (SAC) and sporadic colorectal carcinoma showing histological and molecular features of microsatellite instability (hmMSI-H) are two endpoints...
6.
Romero-Cara P, Torres-Moreno D, Pedregosa J, Vilchez J, Garcia-Simon M, Ruiz-Merino G, et al.
Int J Med Sci
. 2018 Jan;
15(1):10-15.
PMID: 29333082
Background: The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients...
7.
Barh D, Garcia-Solano M, Tiwari S, Bhattacharya A, Jain N, Torres-Moreno D, et al.
Genes (Basel)
. 2017 Sep;
8(10).
PMID: 28956815
The Transcription factor BarH like homeobox 1 (BARHL1) is overexpressed in medulloblastoma and plays a role in neurogenesis. However, much about the BARHL1 regulatory networks and their functions in neurodegenerative...
8.
Gutierrez-Civicos R, Hurtado A, Torres-Moreno D, Sanchez-Blanco J, Espanol I, Consuegra-Sanchez L, et al.
Pharmacogenet Genomics
. 2016 Dec;
27(2):70-77.
PMID: 27977511
Objective: Rituximab in combination with chemotherapy has been proven to increase progression-free and overall survival in follicular lymphoma (FL), but there is considerable interindividual variability in the response. Extrinsic pathway...
9.
Gutierrez-Civicos R, Hurtado A, Torres-Moreno D, Sanchez-Blanco J, Espanol I, Consuegra-Sanchez L, et al.
Am J Hematol
. 2016 Mar;
91(6):E305-7.
PMID: 26950187
No abstract available.
10.
Garcia-Solano J, Garcia-Solano M, Torres-Moreno D, Carbonell P, Trujillo-Santos J, Perez-Guillermo M, et al.
Cell Oncol (Dordr)
. 2016 Feb;
39(3):243-52.
PMID: 26832730
Background: In contrast to conventional colorectal carcinomas (CCs), which develop through a so-called chromosome instability or suppressor phenotype pathway, the sequence of events leading from precursor polyps/adenomas to serrated adenocarcinomas...